//
sign in
Profile
by @danabra.mov
Profile
by @dansshadow.bsky.social
Profile
by @jimpick.com
AviHandle
by @danabra.mov
AviHandle
by @dansshadow.bsky.social
AviHandle
by @katherine.computer
EventsList
by @katherine.computer
ProfileHeader
by @dansshadow.bsky.social
ProfileHeader
by @danabra.mov
ProfileMedia
by @danabra.mov
ProfilePlays
by @danabra.mov
ProfilePosts
by @danabra.mov
ProfilePosts
by @dansshadow.bsky.social
ProfileReplies
by @danabra.mov
Record
by @atsui.org
Skircle
by @danabra.mov
StreamPlacePlaylist
by @katherine.computer
+ new component
ProfilePosts









Loading...
In Wiley Advanced Science @mariesabatier.bsky.social, @ubellackerlab.bsky.social, and colleagues examine GPX4 inhibitor resistance in triple-negative breast cancer, showing that resistant cells survive in circulation but lose the ability to spontaneously metastasize from primary tumors. hsph.me/GPX4
Thanks to James Olzmann and Scott Dixon for organizing a fantastic #faseb #ferroptosis meeting in Scottsdale AZ! Lots of great science as ferroptosis continues to impact diverse biology and diseases. Can’t wait for the next one! @olzmannlab.bsky.social
Hot off the presses! Was an honor to team up with Scott Dixon @stanforduniversity.bsky.social on this Nature Cancer review. We reflect on hurdles that have slowed translation of ferroptosis-directed therapies and share ideas on what it will take to bring these therapies to the clinic. rdcu.be/eBbqV
9mo
2mo
10mo
Interested in studying lymph node metastasis? Check out our protocol by Cort Breuer out today in @natprot.nature.com bsky.app/profile/nat...
Way-to-go Alanis Carmona and Lewis Hendrianto for your incredible posters today at the Landry Cancer Biology Consortium, and shout-out to Alanis on your Karin Grunebaum Cancer Research Foundation Rising Young Scientist Award!
Happy to see our News & Views is out! We highlight two landmark papers demonstrating the potential for therapeutic targeting of FSP1 and #ferroptosis in in vivo cancer models. Beautiful work from @ubellackerlab.bsky.social, Thales Papagiannakopoulos, and colleagues. 🥳 www.nature.com/articles/s41...
Join me in Boston October 6th for a 1-day conference on #mappingbiology to transform #cancertherapeutics. Register by September 25th to benefit from the complimentary (free) admission! Topics, speakers, and talk opportunities here: abcam.me/mappingbiolo... @abcamofficial.bsky.social
Excited to share our work @nature.com! Postdoc @mariopalma.bsky.social, with major contributions from @retickerflynn.bsky.social and collaborators, discovered melanoma cells in lymph nodes gain a targetable FSP1 dependency that limits progression. #TeamFSP1 www.nature.com/articles/s41...
10mo
May 22, 2025
6mo
10mo
7mo
Nature Cancer - Ubellacker and Dixon summarize the latest discoveries on ferroptosis in cancer, covering the molecular and cellular pathways underlying sensitivity and resistance to this type of...
Prospects for ferroptosis therapies in cancer
rdcu.be
Excited to share my postdoctoral work, out today in Nature! www.nature.com/articles/s41... We discovered that melanoma cells in lymph nodes gain a targetable FSP1 dependency that limits melanoma progression.
New Article! Spontaneous and experimental models of lymph node metastasis https://bit.ly/4fzWoAj
bsky.app
7mo
Nature Protocols (@natprot.nature.com)
In vivo models bring FSP1 inhibitors to life - Nature Cell Biology
FSP1 is a key suppressor of lipid peroxidation and ferroptosis, yet it is largely dispensable in standard cell culture models. Two new studies now show that FSP1 becomes essential for tumour growth in...
www.nature.com
www.nature.com
Lymph node environment drives FSP1 targetability in metastasizing melanoma | Nature
Targeting FSP1 in lymph nodes has considerable potential for blocking melanoma progression.
www.nature.com
Lymph node environment drives FSP1 targetability in metastasizing melanoma - Nature
Brent Stockwell
Harvard Molecular Metabolism
Ubellacker Lab
Ubellacker Lab
Ubellacker Lab
Ubellacker Lab
Nathan Reticker-Flynn
James Olzmann
Ferroptosis-targeting therapies in cancer have yet to make it to the clinic. New review published today in Nature Cancer by @ubellackerlab.bsky.social and Scott Dixon of Stanford share hurdles and ideas for future strategies to bring these therapies closer to the clinic. Check it out rdcu.be/eBbqV
9mo
Mario Palma
Grateful to mark ULab’s 3rd birthday surrounded by brilliant minds and a deep sense of belonging. In a time of shifting priorities in academia, I’m especially thankful for the inclusive leadership and unwavering support of my incredible PI, Jessalyn @ubellackerlab.bsky.social
11mo
Nature Cancer - Ubellacker and Dixon summarize the latest discoveries on ferroptosis in cancer, covering the molecular and cellular pathways underlying sensitivity and resistance to this type of...
rdcu.be
Prospects for ferroptosis therapies in cancer
Harvard Molecular Metabolism
It’s over 100°F in Boston, and though both the weather and funding climates are intense, we took a well-deserved ice cream break to celebrate the progress, and the incredible people past and present, behind it all. Happy 3rd birthday, ULab! 🎉
11mo
Ubellacker Lab
Marie Sabatier